News AbbVie’s Skyrizi hits the spot in refractory psoriasis Antibody works when IL-17 inhibitors Like Novartis' Cosentyx and Lilly's Taltz fail.
News Lilly’s Taltz scrapes win against Humira in psoriatic arthri... Eli Lilly’s Taltz has beaten AbbVie’s blockbuster Humira in a psoriatic arthritis study involving patients who hadn’t been treated before with a disease-modifying drug, but only just.
Oncology Treating primary bone cancer: The potential of listeria-base... In a new pharmaphorum podcast, Paul Romness, president and CEO of OS Therapies, discusses the company's work in osteosarcoma.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
